



An Anthem Company

# New York Provider News

August 2019 Empire Provider News

## Pharmacy:

Clinical Criteria and Prior Authorization updates for specialty pharmacy are available . . . . . 3

Reminder: Changes to the process for Medical Non-Oncology Specialty Drug reviews effective June 15, 2019 . . . . . 7

Pharmacy information available on empireblue.com . . . . . 9

## Administrative:

Empire customization's to MCG care guidelines 23rd edition . . . . . 9

New online Provider Manual page . . . . . 10

## Medical Policy & Clinical Guidelines:

Policy updates . . . . . 10

Updates to AIM Advanced Imaging Clinical Appropriateness Guidelines . . . . . 21

Updates to AIM Radiation Oncology: Proton Beam Therapy Clinical Appropriateness Guideline . . . . . 23

Updates to AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline . . . . . 24

## Reimbursement Policies:

Reimbursement Policy Updates . . . . . 25

Update regarding Evaluation and Management with modifier 25 same day as procedure when a prior E/M for the same or similar service has occurred (Professional) . . . . . 26

## Medicaid:

AIM Specialty Health programs may require documentation . . . . . 26

Pharmacy management information . . . . . 27

Use the Provider Maintenance Form to update your information	27
Prepayment clinical validation review process	28
Keep up with Medicaid news	29
 <b>Medicare:</b>	
Medicare Advantage: AIM Specialty Health programs may require documentation	29
Medicare Advantage: New service types added to Availity	30
Medicare Advantage: New Reimbursement Policy: Drug Screen Testing (Policy 19-001, effective 10/01/19)	31
Medicare Advantage: Special needs plans - provider training required	32
Keep up with Medicare news	32

Services provided by Empire HealthChoice HMO, Inc. and/or Empire HealthChoice Assurance, Inc. licensees of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans, serving residents and businesses in the 28 eastern and southeastern counties of New York State. The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. All external sites will open in a new browser window. Please view our Website Privacy Policy for more information.

## Clinical Criteria and Prior Authorization updates for specialty pharmacy are available

Published: Aug 1, 2019 - Products & Programs / Pharmacy

Below are Clinical Criteria and prior authorization updates that were endorsed at the May 17, 2019 Clinical Criteria meeting. To access the clinical criteria information please click [here](#).

Empire's prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Empire's medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health® (AIM), a separate company.

### Revised Clinical Criteria effective June 10, 2019

The following new clinical criteria were revised to expand medical necessity indications or criteria. The table below will assist you in identifying the new document number for the clinical criteria that corresponds with the previous Clinical or Coverage Guideline.

Clinical or Coverage Guideline	Clinical Criteria	Clinical Criteria Name	Drug(s)	HCPCS or CPT Code(s)
CG-DRUG-106	ING-CC-0092	Adcetris (brentuximab)	Adcetris	J9042
CG-DRUG-38	ING-CC-0094	Alimta (pemetrexed)	Alimta	J9305
CG-DRUG-42	ING-CC-0096	Asparagine Specific Enzymes	Erwinaze, Asparaginase, Oncaspar	J9019, J9020, J9266
CG-DRUG-63	ING-CC-0104	Leucovorin and Levoleucovorin agents	Fusilev, Khapzory	J0641, C9043, J3490
CG-DRUG-66	ING-CC-0105	Vectibix (panitumumab)	Vectibix	J9303
CG-DRUG-72	ING-CC-0110	Perjeta (pertuzumab)	Perjeta	J9306
CG-DRUG-96	ING-CC-0115	Kadcyla (ado-trastuzumab)	Kadcyla	J9354
CG-				

DRUG-98	ING-CC-0116	Bendamustine agents	Bendeka, Treanda, Belrapzo	J9034, J9033, C9042, J9999
DRUG.00046	ING-CC-0119	Yervoy (ipilimumab)	Yervoy	J9228
DRUG.00053	ING-CC-0120	Kyprolis (carfilzomib)	Kyprolis	J9047
DRUG.00063	ING-CC-0122	Arzerra (ofatumumab)	Arzerra	J9302
DRUG.00067	ING-CC-0123	Cyramza (ramucirumab)	Cyramza	J9308
DRUG.00071	ING-CC-0124	Keytruda (pembrolizumab)	Keytruda	J9271
DRUG.00075	ING-CC-0125	Opdivo (nivolumab)	Opdivo	J9299
DRUG.00107	ING-CC-0129	Bavencio (avelumab)	Bavencio	J9023

### Revised Clinical Criteria effective September 1, 2019

The following new clinical criteria were reviewed with no significant change to the medical necessity indications or criteria. The table below will assist you in identifying the new document number for the clinical criteria that corresponds with the previous Clinical or Coverage Guideline.

Clinical or Coverage Guideline	Clinical Criteria	Clinical Criteria Name	Drug(s)	HCPCS or CPT Code(s)
CG-DRUG-100	ING-CC-0085	Actimmune (interferon gamma-1B)	Actimmune	J9216
CG-DRUG-101	ING-CC-0090	Ixempra (ixabepilone)	Ixempra	J9207
CG-DRUG-102	ING-CC-0091	Lartruvo (olaratumab)	Lartruvo	J9285
CG-DRUG-49	ING-CC-0098	Doxorubicin Hydrochloride Liposome	Lipodox, Doxorubicin	

hydrochloride liposomal, Doxil	Q2049, Q2050			
CG-DRUG-50	ING-CC-0099	Abraxane (paclitaxel protein-bound)	Abraxane	J9264
CG-DRUG-51	ING-CC-0100	Istodax (romidepsin)	Istodax	J9315
CG-DRUG-62	ING-CC-0103	Faslodex (fulvestrant)	Faslodex	J9395
CG-DRUG-67	ING-CC-0106	Erbitux (cetuximab)	Erbitux	J9055
CG-DRUG-68	ING-CC-0107	Bevacizumab agents (Avastin, Mvasi)	Avastin, Mvasi	J9035, Q5107
CG-DRUG-70	ING-CC-0108	Halaven (eribulin)	Halaven	J9179
CG-DRUG-71	ING-CC-0109	Zaltrap (ziv-aflibercept)	Zaltrap	J9400
CG-DRUG-75	ING-CC-0111	Nplate (romiplostim)	Nplate	J2796
CG-DRUG-77	ING-CC-0112	Xofigo (Radium Ra 223 Dichloride)	Xofigo	A9606, 79101
CG-DRUG-80	ING-CC-0114	Jevtana (cabazitaxel)	Jevtana	J9043
CG-DRUG-99	ING-CC-0117	Empliciti (elotuzumab)	Empliciti	J9176
CG-THER-RAD-03	ING-CC-0118	Radioimmunotherapy: Zevalin; azedra; Lutathera	Zevalin, Azedra, Lutathera	79403, A9543, 79101, A9699, C9408, A9513
DRUG.00062	ING-CC-0121	Gazyva (obinutuzumab)	Gazyva	J9301
DRUG.00076	ING-CC-0126	Blincyto (blinatumomab)	Blincyto	J9039
DRUG.00082	ING-CC-0127	Darzalex (daratumumab)	Darzalex	J9145
DRUG.00088	ING-CC-0128	Tecentriq (atezolizumab)	Tecentriq	J9022

DRUG.00109	ING-CC-0130	Imfinzi (durvalumab)	Imfinzi	J9173
CG-DRUG-113	ING-CC-0131	Besponsa (inotuzumab ozogamicin)	Besponsa	J9229
DRUG.00112	ING-CC-0132	Mylotarg (gemtuzumab ozogamicin)	Mylotarg	J9203
DRUG.00118	ING-CC-0133	Aliqopa (copanlisib)	Aliqopa	J9057
MED.00106	ING-CC-0134	Provenge (Sipuleucel-T)	Provenge	Q2043
CG-MED-67	ING-CC-0135	Melanoma Vaccines	Imlygic	J9325, J3590
CG-DRUG-53	ING-CC-0136	Drug dosage, frequency, and route of administration	N/A	N/A
CG-DRUG-01	ING-CC-0141	Off-Label Drug and Approved Orphan Drug Use	N/A	N/A

### Revised Clinical Criteria effective November 1, 2019

The following current and new clinical criteria were revised and might result in services that were previously covered but may now be found to be not medically necessary.

- ING-CC-0048 Spinraza (nusinersen)
- ING-CC-0002 Colony Stimulating Factor Agents
- ING-CC-0113 Sylvant (siltuximab) [previously CG-DRUG-79]

### New Clinical Criteria effective November 1, 2019

The following clinical criteria are new.

- ING-CC-0137 Cablivi (caplacizumab-yhdp)
- ING-CC-0138 Asparlas (calaspargase pegol-mknl)
- ING-CC-0139 Evenity (romosozumab-aqqg)
- ING-CC-0140 Zulresso (brexanolone)

## Expanded specialty pharmacy prior authorization list

Effective for dates of service on and after November 1, 2019, the following non-oncology specialty pharmacy codes from current clinical criteria will be included in our prior authorization review process.

Please note, inclusion of NDC code on your claim will shorten the claim processing time of drugs billed with a Not Otherwise Classified (NOC) code.

Empire's prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Empire's medical specialty drug review team. Oncology drugs will be managed by AIM Specialty Health® (AIM), a separate company.

Clinical Criteria	HCPCS or CPT Code(s)	NDC Code(s)	Drug
ING-CC-0050	J3490 J3590	00074-2042-01 00074-2042-02	Skyrizi™

URL: <https://providernews.empireblue.com/article/clinical-criteria-and-prior-authorization-updates-for-specialty-pharmacy-are-available>

---

## Reminder: Changes to the process for Medical Non-Oncology Specialty Drug reviews effective June 15, 2019

Published: Aug 1, 2019 - Products & Programs / Pharmacy

In the [June newsletter](#) we announced the transition of the medical non-oncology specialty drug review process from AIM Specialty Health® (AIM) to Empire's medical specialty drug review team, effective June 15, 2019. Here's a reminder of the changes.

### What has changed?

- Beginning June 15, 2019, for all **new** specialty drug review requests and **reauthorization** specialty drug review requests that were previously performed by AIM, providers need to contact Empire's medical specialty drug review team:
- by phone at 1-833-293-0659

- by fax at 1-888-223-0550 or
- All inquiries about an existing request (initially submitted to AIM or Empire), peer-to-peer review, or reconsideration are being managed by Empire’s medical specialty drug review team.

**What has not changed?**

- AIM continues to be responsible for performing **medical oncology drug** reviews for existing commercial medical benefit for our employer group business.
- Specialty drug review processes not previously done by AIM remain unchanged.
- Clinical criteria for **medical non-oncology specialty drugs** continues to reside on the [clinical criteria page](#).
- Post Service Clinical Coverage Reviews and Grievance and Appeals process and teams have not changed.

Here is a summary of the medical specialty drug changes: **Beginning June 15, 2019**

Action	Contact
Submit a new prior authorization request for medical specialty drug reviews  Submit a reauthorization request for a medical specialty drug review previously performed by AIM	Call Empire at 1-833-293-0659  or  Fax us at 1-888-223-0550 for
Inquire about an existing request (initially submitted to AIM or Empire), peer-to-peer review, or reconsideration	Call Empire at 1-833-293-0659

**URL:** <https://providernews.empireblue.com/article/reminder-changes-to-the-process-for-medical-non-oncology-specialty-drug-reviews-effective-june-15-2019>



## Pharmacy information available on empireblue.com

Published: Aug 1, 2019 - **Products & Programs** / Pharmacy

For more information on copayment/coinsurance requirements and their applicable drug classes, drug lists and changes, prior authorization criteria, procedures for generic substitution, therapeutic interchange, step therapy or other management methods subject to prescribing decisions, and any other requirements, restrictions, or limitations that apply to using certain drugs, visit [empireblue.com/pharmacyinformation](http://empireblue.com/pharmacyinformation). The commercial and marketplace drug lists are posted to the web site quarterly (the first of the month for January, April, July and October).

To locate Marketplace scroll down to “Select Drug Lists.” This drug list is also reviewed and updated regularly as needed.

*FEP Pharmacy updates and other pharmacy related information may be accessed at [www.fepblue.org](http://www.fepblue.org) > Pharmacy Benefits.*

**URL:** <https://providernews.empireblue.com/article/pharmacy-information-available-on-empirebluecom-8>

---

## Empire customization's to MCG care guidelines 23rd edition

Published: Aug 1, 2019 - **Administrative**

Effective November 1, 2019, the following MCG care guideline 23rd edition customization will be implemented for Chemotherapy, Inpatient & Surgical Care (W0162) for adult patients. This customization provides specific criteria and guidance on the following:

- Revised Clinical Indications for admission and added examples for:
- Aggressive hydration needs that cannot be managed in an infusion center
- Prolonged marrow suppression
- Added Regimens that cannot be managed as an outpatient with examples

Go online to view the summary of [MCG 23RD edition customizations](#).

For questions, please contact the provider service number on the back of the member's ID card.

URL: <https://providernews.empireblue.com/article/empire-customizations-to-mcg-care-guidelines-23rd-edition>

---

## New online Provider Manual page

Published: Aug 1, 2019 - **Administrative**

Empire has launched a new page on [empireblue.com/provider](http://empireblue.com/provider) to access Provider Manuals. This page delivers a more streamlined and easier user experience to access current and past Manuals (if applicable). To view the new page go to: [empireblue.com/provider](http://empireblue.com/provider) > Scroll down to “[Enjoy Easy Access to Policies and Guidelines](#)” select “See Policies and Guidelines”. From the Policies and Guidelines landing page, there is a link to the [Provider Manual](#) page.

URL: <https://providernews.empireblue.com/article/new-online-provider-manual-page>

---

## Policy updates

Published: Aug 1, 2019 - **Policy Updates** / Medical Policy & Clinical Guidelines

These updates list the new and/or revised Empire medical policies, clinical guidelines and reimbursement policies\*. The implementation date for each policy or guideline is noted for each section. Implementation of the new or revised medical policy, clinical guideline or reimbursement policy is effective for all claims processed on and after the specified implementation date, regardless of date of service. Previously processed claims will not be reprocessed as a result of the changes. If there is any inconsistency or conflict between the brief description provided below and the actual policy or guideline, the policy or guideline will govern.

Federal and state law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over medical policy and clinical guidelines (and medical policy takes precedence over clinical guidelines) and must be considered first in determining eligibility for coverage. The member's contract benefits in effect on the date that the services are rendered must be used. This document supplements any previous

medical policy and clinical guideline updates that may have been issued by Empire. Please include this update with your Provider Manual for future reference.

Please note that medical policy, which addresses medical efficacy, should be considered before utilizing medical opinion in adjudication. Empire's medical policies and clinical guidelines can be found at [empireblue.com](http://empireblue.com).

\*Note: These updates may not apply to all ASO Accounts as some accounts may have non-standard benefits that apply.

## Medical Policy Updates

### Transitioned Medical Policies Effective 06-10-2019

(The following policies have been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- DRUG.00046 - Ipilimumab (Yervoy®) [Transitioned to ING-CC-0119 Yervoy (ipilimumab)]
- DRUG.00053 - Carfilzomib (Kyprolis®) [Transitioned to ING-CC-0120 Kyprolis (carfilzomib)]
- DRUG.00063 - Ofatumumab (Arzerra®) [Transitioned to ING-CC-0122 Arzerra (ofatumumab)]
- DRUG.00067 - Ramucirumab (Cyramza®) [Transitioned to ING-CC-0123 Cyramza (ramucirumab)]
- DRUG.00071 - Pembrolizumab (Keytruda®) [Transitioned to ING-CC-0124 Keytruda (pembrolizumab)]
- DRUG.00075 - Nivolumab (Opdivo®) [Transitioned to ING-CC-0125 Opdivo (nivolumab)]
- DRUG.00107 - Avelumab (Bavencio®) [Transitioned to ING-CC-0129 Bavencio (avelumab)]

### New Medical Policy Effective 06-13-2019

(The following policy is new and determined to not have significant changes.)

- MED.00129 - Gene Therapy for Spinal Muscular Atrophy

#### Revised Medical Policies Effective 06-13-2019

(The following policies were revised to expand medical necessity indications or criteria.)

- GENE.00029 - Genetic Testing for Breast and/or Ovarian Cancer Syndrome
- SURG.00011 - Allogeneic, Xenographic, Synthetic and Composite Products for Wound Healing and Soft Tissue Grafting
- SURG.00023 - Breast Procedures; including Reconstructive Surgery, Implants and Other Breast Procedures

#### Revised Medical Policy Effective 06-15-2019

(The following policy was revised to expand medical necessity indications or criteria.)

- SURG.00028 - Surgical and Minimally Invasive Treatments for Benign Prostatic Hyperplasia (BPH) and Other Genitourinary Conditions

#### Revised Medical Policies Effective 06-27-2019

(The following policies were revised to expand medical necessity indications or criteria.)

- DRUG.00062 - Obinutuzumab (Gazyva®)
- GENE.00044 - Analysis of PIK3CA Status in Tumor Cells

#### Revised Medical Policies Effective 06-27-2019

(The following policies were reviewed and had no significant changes to the policy position or criteria.)

- GENE.00025 - Molecular Profiling and Proteogenomic Testing for the Evaluation of Malignancies
- GENE.00028 - Genetic Testing for Colorectal Cancer Susceptibility
- SURG.00010 - Treatments for Urinary Incontinence
- SURG.00121 - Transcatheter Heart Valve Procedures

#### Revised Medical Policies Effective 06-27-2019

(The following policies were updated with the new CPT/HCPCS procedure codes effective on 06-27-2019.)

- GENE.00001 - Genetic Testing for Cancer Susceptibility
- GENE.00043 - Genetic Testing of an Individual's Genome for Inherited Diseases
- LAB.00011 - Analysis of Proteomic Patterns
- LAB.00015 - Detection of Circulating Tumor Cells in the Blood as a Prognostic Factor for Cancer

#### Revised Medical Policy Effective 07-10-2019

(The following policy was revised to expand medical necessity indications or criteria.)

- MED.00109 - Corneal Collagen Cross-Linking

#### Revised Medical Policies Effective 07-10-2019

(The following policies were reviewed and had no significant changes to the policy position or criteria.)

- ADMIN.00002 - Preventive Health Guidelines
- ADMIN.00004 - Medical Necessity Criteria
- ADMIN.00005 - Investigational Criteria
- ADMIN.00007 - Immunizations
- ANC.00006 - Biomagnetic Therapy
- ANC.00007 - Cosmetic and Reconstructive Services: Skin Related
- DME.00024 - Transtympanic Micropressure for the Treatment of Ménière's Disease
- DME.00030 - Altered Auditory Feedback Devices for the Treatment of Stuttering
- DME.00034 - Standing Frames
- DME.00037 - Cooling Devices and Combined Cooling/Heating Devices
- DME.00039 - Prefabricated Oral Appliances for the Treatment of Obstructive Sleep Apnea
- GENE.00011 - Gene Expression Profiling for Managing Breast Cancer Treatment
- GENE.00041 - Genetic Testing to Confirm the Identity of Laboratory Specimens
- GENE.00042 - Genetic Testing for Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Syndrome
- GENE.00049 - Circulating Tumor DNA Testing for Cancer (Liquid Biopsy)
- LAB.00016 - Fecal Analysis in the Diagnosis of Intestinal Disorders

- LAB.00031 - Advanced Lipoprotein Testing
- LAB.00035 - Multi-biomarker Disease Activity Blood Tests for Rheumatoid Arthritis
- MED.00090 - Wireless Capsule for the Evaluation of Suspected Gastric and Intestinal Motility Disorders
- MED.00098 - Hyperoxemic Reperfusion Therapy
- MED.00106 - Sipuleucel-T (Provenge®)
- MED.00123 - Axicabtagene ciloleucel (Yescarta®)
- MED.00124 - Tisagenlecleucel (Kymriah®)
- MED.00127 - Chelation Therapy
- OR-PR.00005 - Upper Extremity Myoelectric Orthoses
- RAD.00034 - Dynamic Spinal Visualization (Including Digital Motion X-ray and Cineradiography/ Videofluoroscopy)
- RAD.00063 - Magnetization-Prepared Rapid Acquisition Gradient Echo Magnetic Resonance Imaging (MPRAGE MRI)
- SURG.00005 - Partial Left Ventriculectomy
- SURG.00071 - Percutaneous and Endoscopic Spinal Surgery
- SURG.00076 - Nerve Graft after Prostatectomy
- SURG.00077 - Uterine Fibroid Ablation: Laparoscopic or Percutaneous Image Guided Techniques
- SURG.00084 - Implantable Middle Ear Hearing Aids
- SURG.00105 - Bicompartamental Knee Arthroplasty
- SURG.00116 - High Resolution Anoscopy Screening for Anal Intraepithelial Neoplasia (AIN) and Squamous Cell Cancer of the Anus
- SURG.00118 - Bronchial Thermoplasty
- SURG.00125 - Radiofrequency and Pulsed Radiofrequency Treatment of Trigger Point Pain
- SURG.00126 - Irreversible Electroporation
- SURG.00134 - Interspinous Process Fixation Devices
- SURG.00140 - Peripheral Nerve Blocks for Treatment of Neuropathic Pain
- SURG.00141 - Doppler-Guided Transanal Hemorrhoidal Dearterialization
- SURG.00143 - Perirectal Spacers for Use During Prostate Radiotherapy
- SURG.00147 - Synthetic Cartilage Implant for Metatarsophalangeal Joint Disorders

#### Revised Medical Policy Effective 07-20-2019

(The following policy was reviewed and had no significant changes to the policy position or criteria.)

- SURG.00032 - Transcatheter Closure of Patent Foramen Ovale and Left Atrial Appendage for Stroke Prevention

#### Transitioned Medical Policies Effective 09-01-2019

(The following policies have been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- DRUG.00062 - Obinutuzumab (Gazyva®) [Transitioned to ING-CC-0121 Gazyva (obinutuzumab)]
- DRUG.00076 - Blinatumomab (Blinicyto®) [Transitioned to ING-CC-0126 Blincyto (blinatumomab)]
- DRUG.00082 - Daratumumab (DARZALEX®) [Transitioned to ING-CC-0127 Darzalex (daratumumab)]
- DRUG.00088 - Atezolizumab (Tecentriq®) [Transitioned to ING-CC-0128 Tecentriq (atezolizumab)]
- DRUG.00109 - Durvalumab (Imfinzi®) [Transitioned to ING-CC-0130 Imfinzi (durvalumab)]
- DRUG.00112 - Gemtuzumab Ozogamicin (Mylotarg®) [Transitioned to ING-CC-0132 Mylotarg (gemtuzumab ozogamicin)]
- DRUG.00118 - Copanlisib (Aliqopa®) [Transitioned to ING-CC-0133 Aliqopa (copanlisib)]
- MED.00106 - Sipuleucel-T (Provenge®) [Transitioned to ING-CC-0134 Provenge (Sipuleucel-T)]

#### Revised Medical Policy Effective 09-04-2019

(The following policy was reviewed and had no significant changes to the policy position or criteria.)

- GENE.00010 - Genotype Panel Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status [Note: Genotype testing for single polymorphisms of metabolizing enzymes for specific drugs moved into a separate clinical utilization management guideline, CG-GENE-11 Genotype Testing for Individual Genetic Polymorphisms to Determine Drug-Metabolizer Status.]

#### Archived Medical Policies Effective 09-04-2019

(The following policies have been archived and their content has been transferred to new Clinical UM Guidelines.)

- GENE.00021 - Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies [Note: Content transferred to CG-GENE-10 Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies]
- SURG.00106 - Ablative Techniques as a Treatment for Barrett's Esophagus Anomalies [Note: Content transferred to CG-SURG-101 Ablative Techniques as a Treatment for Barrett's Esophagus]
- SURG.00133 - Alcohol Septal Ablation for Treatment of Hypertrophic Cardiomyopathy [Note: Content transferred to CG-SURG-102 Alcohol Septal Ablation for Treatment of Hypertrophic Cardiomyopathy]

#### New Medical Policy Effective 11-01-2019

(The policy below was created and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational.)

- GENE.00051 - Bronchial Gene Expression Classification for Diagnostic Evaluation of Lung Cancer

#### Revised Medical Policies Effective 11-01-2019

(The policies below were revised and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational.)

- DME.00038 - Static Progressive Stretch (SPS) and Patient-Actuated Serial Stretch (PASS) Devices
- LAB.00027 - Selected Blood, Serum and Cellular Allergy and Toxicity Tests
- LAB.00033 - Protein Biomarkers for the Screening, Detection and Management of Prostate Cancer
- OR-PR.00003 - Microprocessor Controlled Lower Limb Prostheses
- SURG.00120 - Internal Rib Fixation Systems



#### New Medical Policy Effective 11-09-2019

(The policy below was created and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational.)

- SURG.00153 - Cardiac Contractility Modulation Therapy

#### Revised Medical Policy Effective 11-09-2019

(The policy below was revised and might result in services that were previously covered but may now be found to be either not medically necessary and/or investigational.)

- SURG.00045 - Extracorporeal Shock Wave Therapy

### **Clinical Guideline Updates**

#### Transitioned Clinical Guidelines Effective 06-10-2019

(The following adopted guidelines have been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- CG-DRUG-38 - Pemetrexed Disodium (Alimta®) [Transitioned to ING-CC-0094 Alimta (pemetrexed)]
- CG-DRUG-42 - Asparagine Specific Enzymes (Asparaginase) [Transitioned to ING-CC-0096 Asparagine Specific Enzymes]
- CG-DRUG-63 - Levoleucovorin Products [Transitioned to ING-CC-0104 Levoleucovorin Agents]
- CG-DRUG-66 - Panitumumab (Vectibix®) [Transitioned to ING-CC-0105 Vectibix (panitumumab)]
- CG-DRUG-72 - Pertuzumab (Perjeta®) [Transitioned to ING-CC-0110 Perjeta (pertuzumab)]
- CG-DRUG-96 - Ado-trastuzumab emtansine (Kadcyla®) [Transitioned to ING-CC-0115 Kadcyla (ado-trastuzumab)]
- CG-DRUG-98 - Bendamustine Hydrochloride [Transitioned to ING-CC-0116 Bendamustine agents]
- CG-DRUG-106 - Brentuximab Vedotin (Adcetris®) [Transitioned to ING-CC-0092 Adcetris (brentuximab)]

#### Revised Clinical Guideline Effective 06-27-2019

(The following adopted guideline was revised to expand medical necessity indications or criteria.)

- CG-DRUG-62 - Fulvestrant (FASLODEX®)

Revised Clinical Guideline Effective 07-10-2019

(The following adopted guideline was revised to expand medical necessity indications or criteria.)

- CG-MED-59 - Upper Gastrointestinal Endoscopy in Adults

Revised Clinical Guidelines Effective 07-10-2019

(The following adopted guidelines were reviewed and had no significant changes to the policy position or criteria.)

- CG-DME-45 - Ultrasound Bone Growth Stimulation
- CG-GENE-02 - Analysis of KRAS Status
- CG-MED-64 - Transcatheter Ablation of Arrhythmogenic Foci in the Pulmonary Veins as a Treatment of Atrial Fibrillation or Atrial Flutter (Radiofrequency and Cryoablation)
- CG-MED-74 - Implantable Ambulatory Event Monitors and Mobile Cardiac Telemetry
- CG-MED-75 - Medical and Other Non-Behavioral Health Related Treatments for Autism Spectrum Disorders and Rett Syndrome
- CG-MED-76 - Magnetic Source Imaging and Magnetoencephalography
- CG-MED-77 - SPECT/CT Fusion Imaging
- CG-MED-83 - Level of Care: Specialty Pharmaceuticals
- CG-REHAB-11 - Cognitive Rehabilitation
- CG-SURG-05 - Maze Procedure
- CG-SURG-08 - Sacral Nerve Stimulation as a Treatment of Neurogenic Bladder Secondary to Spinal Cord Injury
- CG-SURG-12 - Penile Prosthesis Implantation
- CG-SURG-34 - Diagnostic Infertility Surgery
- CG-SURG-35 - Intracytoplasmic Sperm Injection (ICSI)
- CG-SURG-49 - Endovascular Techniques (Percutaneous or Open Exposure) for Arterial Revascularization of the Lower Extremities
- CG-SURG-50 - Assistant Surgeons

- CG-SURG-81 - Cochlear Implants and Auditory Brainstem Implants
- CG-SURG-82 - Bone-Anchored and Bone Conduction Hearing Aids
- CG-SURG-84 - Mandibular/ Maxillary (Orthognathic) Surgery
- CG-SURG-85 - Hip Resurfacing
- CG-SURG-86 - Endovascular/Endoluminal Repair of Aortic Aneurysms, Aortoiliac Disease, Aortic Dissection and Aortic Transection
- CG-SURG-87 - Nasal Surgery for the Treatment of Obstructive Sleep Apnea and Snoring
- CG-SURG-88 - Mastectomy for Gynecomastia
- CG-SURG-89 - Radiofrequency Neurolysis and Pulsed Radiofrequency Therapy for Trigeminal Neuralgia
- CG-TRANS-03 - Donor Lymphocyte Infusion for Hematologic Malignancies after Allogeneic Hematopoietic Progenitor Cell Transplantation

#### Transitioned Clinical Guideline Effective 08-01-2019

(The following adopted guideline has been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- CG-DRUG-76 - Plerixafor Injection (Mozobil™) [Transitioned to ING-CC-0089 Mozobil (plerixafor)]

#### Transitioned Clinical Guidelines Effective 09-01-2019

(The following adopted guidelines have been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- CG-DRUG-01 - Off-Label Drug and Approved Orphan Drug Use [Transitioned to ING-CC-0141 Off-Label Drug and Approved Orphan Drug Use]
- CG-DRUG-49 - Doxorubicin Hydrochloride Liposome Injection [Transitioned to ING-CC-0098 Doxorubicin Hydrochloride Liposome]
- CG-DRUG-50 - Paclitaxel, protein-bound (Abraxane®) [Transitioned to ING-CC-0099 Abraxane (paclitaxel protein-bound)]
- CG-DRUG-51 - Romidepsin (Istodax®) [Transitioned to ING-CC-0100 Istodax (romidepsin)]
- CG-DRUG-53 - Drug Dosage, Frequency, and Route of Administration [Transitioned to ING-CC-0136 Dose, frequency, and route of administration]

- CG-DRUG-62 - Fulvestrant (FASLODEX®) [Transitioned to ING-CC-0103 Faslodex (fulvestrant)]
- CG-DRUG-67 - Cetuximab (Erbix®) [Transitioned to ING-CC-0106 Erbitux (cetuximab)]
- CG-DRUG-68 - Bevacizumab (Avastin®) for Non-Ophthalmologic Indications [Transitioned to ING-CC-0107 Bevacizumab for Non-ophthalmologic Indications (Avastin, Mvasi)]
- CG-DRUG-70 - Eribulin mesylate (Halaven®) [Transitioned to ING-CC-0108 Halaven (eribulin)]
- CG-DRUG-71 - Ziv-aflibercept (Zaltrap®)[Transitioned to ING-CC-0109 Zaltrap (ziv-aflibercept)]
- CG-DRUG-75 - Romiplostim (Nplate®) [Transitioned to ING-CC-0111 Nplate (romiplostim)]
- CG-DRUG-77 - Radium Ra 223 Dichloride (Xofigo®)[Transitioned to ING-CC-0112 Xofigo (Radium Ra 223 Dichloride)]
- CG-DRUG-80 - Cabazitaxel (Jevtana®) [Transitioned to ING-CC-0114 Jevtana (cabazitaxel)]
- CG-DRUG-99 - Elotuzumab (Empliciti™) [Transitioned to ING-CC-0117 Empliciti (elotuzumab)]
- CG-DRUG-100 - Interferon gamma-1b (Actimmune®) [Transitioned to ING-CC-0085 Actimmune (interferon gamma-1B)]
- CG-DRUG-101 - Ixabepilone (Ixempra®) [Transitioned to ING-CC-0090 Ixempra (ixabepilone)]
- CG-DRUG-102 - Olaratumab (Lartruvo™) [Transitioned to ING-CC-0091 Lartruvo (olaratumab)]
- CG-DRUG-113 - Inotuzumab ozogamicin (Besponsa®) [Transitioned to ING-CC-0131 Besponsa (inotuzumab ozogamicin)]
- CG-MED-67 - Melanoma Vaccines [Transitioned to ING-CC-0135 Melanoma Vaccines]
- CG-THER-RAD-03 - Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy [Transitioned to ING-CC-0118 Radioimmunotherapy: Zevalin; azedra; Lutathera]

Adopted Clinical Guidelines Effective 09-04-2019

(The following guidelines were previously medical policies and have been adopted and have no significant changes.)

- CG-GENE-10 - Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies [Note: Content moved from GENE.00021 Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder) and Congenital Anomalies.]
- CG-GENE-11 - Genotype Testing for Individual Genetic Polymorphisms to Determine Drug-Metabolizer Status [Note: Content for genotype testing for single polymorphisms of metabolizing enzymes for specific drugs moved from GENE.00010 Genotype Testing for Genetic Polymorphisms to Determine Drug-Metabolizer Status.]
- CG-SURG-101 - Ablative Techniques as a Treatment for Barrett's Esophagus [Note: Content moved from SURG.00106 Ablative Techniques as a Treatment for Barrett's Esophagus Anomalies.]

Transitioned Clinical Guideline Effective 11-01-2019

(The following adopted guideline has been transitioned to Pharmacy and Therapeutics (P&T) Clinical Criteria.)

- CG-DRUG-79 - Siltuximab (Sylvant®) [Transitioned to ING-CC-0113 Sylvant (siltuximab)]

URL: <https://providernews.empireblue.com/article/policy-updates-6>

---

## Updates to AIM Advanced Imaging Clinical Appropriateness Guidelines

Published: Aug 1, 2019 - **Policy Updates** / Medical Policy & Clinical Guidelines

Effective for dates of service on and after November 10, 2019, the following updates will apply to the AIM Advanced Imaging Clinical Appropriateness Guidelines.

### **Oncologic Imaging Guideline contains updates to the following:**

- Colorectal cancer, germ cell tumors, kidney cancer, multiple myeloma, prostate cancer and cancers of unknown primary / cancers not otherwise specified,
- Added new sections on hepatobiliary cancer and suspected metastases

- Added allowance for MRI and/or MRCP for diagnostic workup of hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma
- Added allowance for PET “When standard imaging prior to planned curative surgery for cholangiocarcinoma has been performed and has not demonstrated metastatic disease”

**Vascular Imaging Guideline contains updates to the following:**

- Brain, Head and Neck: Aneurysm - intracranial, Aneurysm - extracranial, Arteriovenous malformation (AVM) and fistula (AVF), Fibromuscular dysplasia, Hemorrhage - intracranial, Stenosis or occlusion - extracranial, Stenosis or occlusion - intracranial, stroke and Venous thrombosis or compression - intracranial
- Chest: Acute aortic syndrome, Aortic aneurysm, Pulmonary artery hypertension
- Abdomen and Pelvis: Acute aortic syndrome, Aneurysm of the abdominal aorta or iliac arteries, Hematoma/hemorrhage within the abdomen or unexplained hypotension, Renal artery stenosis (RAS)/Renovascular hypertension, Venous thrombosis or compression – intracranial, Stenosis or occlusion of the abdominal aorta or branch vessels, not otherwise specified
- Upper Extremity: Peripheral arterial disease, Venous thrombosis or occlusion
- Lower Extremity: Added physiologic testing for peripheral arterial disease and further defined indications for classic presenting symptoms of lower extremity peripheral arterial disease
- Added arterial ultrasound guideline content
- Aligned peripheral arterial ultrasound with advanced vascular imaging criteria

**Imaging of the Heart Guideline contains updates to the following:**

- Blood Pool Imaging: Changes address appropriate evaluation and surveillance of LV function in patients following cardiac transplantation. Additional language is more restrictive based on the literature and aligns with the resting transthoracic echocardiography guideline.
- Cardiac CT: Quantitative evaluation of coronary artery calcification has been revised with new more expansive language based on review of the literature.

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's **ProviderPortal**SM directly at [providerportal.com](http://providerportal.com). Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at [availity.com](http://availity.com)
- Call the AIM Contact Center toll-free number: 1-877-430-2288, Monday–Friday, 8:00 a.m.–6:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at [aim.guidelines@aimspecialtyhealth.com](mailto:aim.guidelines@aimspecialtyhealth.com). Additionally, you may access and download a copy of the current guidelines [here](#).

URL: <https://providernews.empireblue.com/article/updates-to-aim-advanced-imaging-clinical-appropriateness-guidelines-8>

---

## Updates to AIM Radiation Oncology: Proton Beam Therapy Clinical Appropriateness Guideline

Published: Aug 1, 2019 - **Policy Updates** / Medical Policy & Clinical Guidelines

Effective for dates of service on and after November 10, 2019, the following updates will apply to the AIM Radiation Oncology: Proton Beam Therapy Clinical Appropriateness Guideline.

- Sinonasal cancer: Added criteria and diagnosis codes for locally advanced sinonasal cancer when tumor involves base of skull and proton beam therapy is needed to spare orbit, optic nerve, optic chiasm, or brainstem
- Ocular Melanoma: Removed tumor size restrictions for treating melanoma of the uveal tract
- Pediatric tumors: Clarified proton beam therapy appropriate for all pediatric tumors requiring radiation therapy

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:

- Access AIM's **ProviderPortal**SM directly at [providerportal.com](http://providerportal.com). Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at [availity.com](http://availity.com)
- Call the AIM Contact Center toll-free number: 1-877-430-2288, Monday–Friday, 8:00 a.m.–6:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at [aim.guidelines@aimspecialtyhealth.com](mailto:aim.guidelines@aimspecialtyhealth.com). Additionally, you may access and download a copy of the current guidelines [here](#).

Please note, this program does not apply to FEP or National Accounts.

**URL:** <https://providernews.empireblue.com/article/updates-to-aim-radiation-oncology-proton-beam-therapy-clinical-appropriateness-guideline>

---

## Updates to AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline

Published: Aug 1, 2019 - **Policy Updates** / Medical Policy & Clinical Guidelines

Effective for dates of service on and after July 14, 2019, the following updates will apply to the AIM Advanced Oncologic Imaging Clinical Appropriateness Guideline.

- Prostate Cancer - Added criteria for the appropriate use of PET-CT with the radiotracers Axumin and 11-Choline, establishing the position of this test in the care continuum for prostate cancer primarily related to biochemical recurrence
- Neuroendocrine Tumors - Added criteria for the appropriate use of PET-CT with the radiotracer DOTA-TATE , establishing the position of this test in the care continuum for neuroendocrine tumors

As a reminder, ordering and servicing providers may submit prior authorization requests to AIM in one of several ways:



- Access AIM's **ProviderPortal**SM directly at [providerportal.com](http://providerportal.com). Online access is available 24/7 to process orders in real-time, and is the fastest and most convenient way to request authorization.
- Access AIM via the Availity Web Portal at [availability.com](http://availability.com)
- Call the AIM Contact Center toll-free number: 1-877-430-2288, Monday–Friday, 8:00 a.m.–6:00 p.m. ET.

For questions related to guidelines, please contact AIM via email at [aim.guidelines@aimspecialtyhealth.com](mailto:aim.guidelines@aimspecialtyhealth.com). Additionally, you may access and download a copy of the current guidelines [here](#).

URL: <https://providernews.empireblue.com/article/updates-to-aim-advanced-oncologic-imaging-clinical-appropriateness-guideline>

---

## Reimbursement Policy Updates

Published: Aug 1, 2019 - **Policy Updates** / Reimbursement Policies

### **Bundled Services - Professional**

Beginning with dates of service on or after November 1, 2019, new Interprofessional CPT codes 99451 and 99452 are not eligible for reimbursement when they are reported with another service or reported as a stand-alone service. These codes have been added to policy section 1 of the Bundled Services and Supplies reimbursement policy.

### **Frequency Editing - Professional**

Our Frequency Editing policy applies frequency maximums per day and/or per date span within the same grouping which may be based on the CMS's MUEs, industry standards, and/or code description. Beginning with dates of service November 1, 2019, maximum units per day may be based on claims data analysis.

URL: <https://providernews.empireblue.com/article/reimbursement-policy-updates-4>

---

## Update regarding Evaluation and Management with modifier 25 same day as procedure when a prior E/M for the same or similar service has occurred (Professional)

Published: Aug 1, 2019 - **Policy Updates** / Reimbursement Policies

Empire has identified that providers often bill a duplicate Evaluation and Management (E/M) service on the same day as a procedure even when the same provider (or a provider with the same specialty within the same group TIN) recently billed a service or procedure which included an E/M for the same or similar diagnosis. The use of modifier 25 to support separate payment of this duplicate service is not consistent with correct coding or Empire's policy on use of modifier 25.

Beginning with claims processed on or after September 1, 2019 Empire may deny the E/M service with a modifier 25 billed on the day of a related procedure when there is a recent service or procedure for the same or similar diagnosis on record.

If you believe a claim should be reprocessed because there are medical records for related visits that demonstrate an unrelated, significant, and separately identifiable E/M service, please submit those medical records for consideration.

**URL:** <https://providernews.empireblue.com/article/update-regarding-evaluation-and-management-with-modifier-25-same-day-as-procedure-when-a-prior-em-for-the-same-or-similar-service-has-occurred-professional-4>

---

## AIM Specialty Health programs may require documentation

Published: Aug 1, 2019 - **State & Federal** / Medicaid

### **Category: Medicaid**

Currently, providers submit various pre-service requests to AIM Specialty Health® (AIM). As part of our ongoing quality improvement efforts for outpatient diagnostic imaging services, cardiac procedures and sleep studies, AIM may request documentation to support the clinical appropriateness of certain requests.

When requested, providers should verify information by submitting documentation from the medical record and/or participating in a pre-service consultation with an AIM physician

reviewer. If medical necessity is not supported, the request may be denied as not medically necessary.

Should you have any questions, please call Provider Services toll free at **1-800-450-8753**.

NYE-NU-0141-19  
501337MUPENMUB

URL: <https://providernews.empireblue.com/article/aim-specialty-health-programs-may-require-documentation>

---

## Pharmacy management information

Published: Aug 1, 2019 - **State & Federal** / Medicaid

**Category: Medicaid**

### Need up-to-date pharmacy information?

Log in to our provider website ([www.empireblue.com/nymedicaidoc](http://www.empireblue.com/nymedicaidoc)) to access our *Formulary*, *Prior Authorization* form, *Preferred Drug List* and process information.

### Have questions about the *Formulary* or need a paper copy?

Call our Pharmacy department at 1-800-450-8753. Our Member Services representatives serve as advocates for our members. To reach Member Services, please call 1-800-300-8181.

NYE-NU-0146-19

URL: <https://providernews.empireblue.com/article/pharmacy-management-information-2>

---

## Use the Provider Maintenance Form to update your information

Published: Aug 1, 2019 - **State & Federal** / Medicaid

**Category: Medicaid**

We continually update our provider directories to ensure that your current practice information is available to our members. At least 30 days prior to making any changes to your practice — including updating your address and/or phone number, adding or deleting a physician from your practice, closing your practice to new patients, etc. — please notify us by completing the Provider Maintenance Form available at <https://www.empireblue.com/provider/provider-maintenance-form>. Thank you for your help and continued efforts in keeping our records up to date.

NYE-NU-0146-19

URL: <https://providernews.empireblue.com/article/use-the-provider-maintenance-form-to-update-your-information-1>

---

## Prepayment clinical validation review process

Published: Aug 1, 2019 - **State & Federal** / Medicaid

### Category: Medicaid

Effective with dates of service on or after September 5, 2019, Empire BlueCross BlueShield HealthPlus will update our audit process for claims with modifiers used to bypass claim edits. Modifier reviews will be conducted through a prepayment clinical validation review process. Claims with modifiers such as -25, -59, -57, LT/RT and other anatomical modifiers will be part of this review process.

In accordance with published reimbursement policies that document proper usage and submission of modifiers, the clinical validation review process will evaluate the proper use of these modifiers in conjunction with the edits they are bypassing (such as NCCI). Clinical analysts who are registered nurses and certified coders will review claims pended for validation, along with any related services, to determine whether it is appropriate for the modifier to bypass the edit.

If you believe a claim reimbursement decision should be reviewed, please follow the normal provider claims payment dispute process and include medical records that support the usage of the modifier applied when submitting claims for consideration.

For more information, contact your Provider Relations representative or call Provider Services at **1-800-450-8753**.

NYE-NU-0133-19  
501184MUPENMUB

URL: <https://providernews.empireblue.com/article/prepayment-clinical-validation-review-process>

---

## Keep up with Medicaid news

Published: Aug 1, 2019 - **State & Federal** / Medicaid

Please continue to check [Medicaid Provider Communications & Updates](#) at [www.empireblue.com/nymedicaidoc](http://www.empireblue.com/nymedicaidoc) for the latest Medicaid information, including:

- [New Reimbursement Policy: Drug Screen Testing](#)
- [Prior authorization requirements for hyperbaric oxygen and supervision of hyperbaric oxygen therapy](#)
- [January 2019 Medical Policies and Clinical Utilization Management Guidelines Update](#)
- [Reimbursement Policy Update: Multiple Radiology Payment Reduction](#)

URL: <https://providernews.empireblue.com/article/keep-up-with-medicaid-news-4>

---

## Medicare Advantage: AIM Specialty Health programs may require documentation

Published: Aug 1, 2019 - **State & Federal** / Medicare

Currently, providers submit various pre-service requests to AIM Specialty Health® (AIM). As part of our ongoing quality improvement efforts for outpatient diagnostic imaging services, cardiac procedures and sleep studies, AIM may request documentation to support the clinical appropriateness of certain requests.

When requested, providers should verify information by submitting documentation from the medical record and/or participating in a pre-service consultation with an AIM physician

reviewer. If medical necessity is not supported, the request may be denied as not medically necessary.

Should you have any questions, please call the number on the back of the member ID card..

NYE-NU-0141-19  
501337MUPENMUB

URL: <https://providernews.empireblue.com/article/medicare-advantage-aim-specialty-health-programs-may-require-documentation>

---

## Medicare Advantage: New service types added to Availity

Published: Aug 1, 2019 - **State & Federal** / Medicare

Enhancements have been made to the Availity Portal that will now allow you to access more service types when using the Eligibility and Benefits Inquiry tool and will also allow us to share even more valuable information with you electronically.

You may have already noticed new additions to service types, including:

- Medically related transportation.
- Long-term care.
  
- Acupuncture.
- Respite care.
- Dermatology.
- Sleep study therapy (found under diagnostic medical).
- Allergy testing.

Note, although there is an extensive list of available benefit types available when submitting an eligibility and benefits request, these types do vary by payer.

Here are some important points to remember when selecting service types:

- The benefit/service type field is populated with the last benefit type you selected. If you don't see a specific benefit in the results, submit a new request and select the specific benefit type/service code.
- You have the ability to inquire about 50 patients at one time using the Add Multiple Patients feature.

EBSCRNU-0062-19  
501372MUPENMUB

URL: <https://providernews.empireblue.com/article/medicare-advantage-new-service-types-added-to-availability>

---

## **Medicare Advantage: New Reimbursement Policy: Drug Screen Testing (Policy 19-001, effective 10/01/19)**

Published: Aug 1, 2019 - **State & Federal** / Medicare

Empire BlueCross BlueShield (Empire) Medicare Advantage allows reimbursement for presumptive and definitive drug screening services. In certain circumstances, Empire Medicare Advantage allows reimbursement for presumptive drug testing by instrumented chemistry analyzers and definitive drug screening services for the same member provided on the same day by a reference laboratory.

Definitive drug testing may be done to confirm the results of a negative presumptive test or to identify substances when there is no presumptive test available. Provider's documentation and member's medical records should reflect that the test was properly ordered and support that the order was based on the result of the presumptive test.

In the event a reference lab (POS = 81) performs both presumptive and definitive tests on the same date of service, records should reflect that the ordering/treating provider issued a subsequent order for definitive testing based on the results of the presumptive tests.

For additional information, refer to the Drug Screen Testing reimbursement policy at [www.empireblue.com/medicareprovider](http://www.empireblue.com/medicareprovider).

EBSCRNU-0024-19 June 2019

501120MUPENMUB

URL: <https://providernews.empireblue.com/article/medicare-advantage-new-reimbursement-policy-drug-screen-testing-policy-19-001-effective-100119>

---

## Medicare Advantage: Special needs plans - provider training required

Published: Aug 1, 2019 - **State & Federal** / Medicare

Empire BlueCross BlueShield offers special needs plans (SNPs) to people eligible for either Medicare and Medicaid benefits or who are qualified Medicare Advantage beneficiaries. SNPs provide enhanced benefits to people eligible for both Medicare and Medicaid. These include supplemental benefits such as hearing, dental, vision and transportation to medical appointments. Some SNPs include a card or catalog for purchasing over-the-counter items. SNPs do not charge premiums. As you are aware, CMS regulations protect SNP members from balance billing.

Providers who are contracted for SNPs are required to take [annual training](#) to stay current on plan benefits and requirements, including coordination-of-care and model-of-care elements. Providers contracted for our SNPs received notices in the first quarter of 2019 containing information for online, self-paced training through our training site hosted by SkillSoft. Each provider contracted for our SNPs is required to complete this annual training and select the attestation stating they have completed the training. Attestations can be completed by individual providers or at the group level with one signature.

EBSCRNU-0032-19  
75429MUSENMUB

URL: <https://providernews.empireblue.com/article/medicare-advantage-special-needs-plans-provider-training-required>

---

## Keep up with Medicare news

Published: Aug 1, 2019 - **State & Federal** / Medicare

Please continue to check [Important Medicare Advantage Updates](#) at



[empireblue.com/medicareprovider](https://empireblue.com/medicareprovider) for the latest Medicare Advantage information, including:

- [Notice of change in Medicare Advantage non-PCP reimbursement status](#)
- [Hearing Care Solutions now serves individual Medicare Advantage members in CT, NY, VA and all Group Retiree Solutions members](#)
- [Update to Emergency Department: Level of E&M Services Reimbursement Policy](#)
- [Prepayment clinical validation review process](#)
- [Unspecified diagnosis code update](#)
- [Medicare Advantage Group Retiree PPO plans and National Access Plus FAQ](#)
- [Group Retiree members and National Access Plus](#)

EBSCRNU-0034-19  
75743MUPENMUB

**URL:** <https://providernews.empireblue.com/article/keep-up-with-medicare-news-73>

---